Both Celsion Corporation (NASDAQ:CLSN) and Cellectis S.A. (NASDAQ:CLLS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celsion Corporation	N/A	74.55	22.04M	-1.29	0.00
Cellectis S.A.	21.43M	36.23	78.69M	-2.11	0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Celsion Corporation and Cellectis S.A.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
Celsion Corporation	0.00%	-104.2%	-48.5%
Cellectis S.A.	-367.20%	-23%	-18.8%

Risk & Volatility

Celsion Corporation is 120.00% more volatile than S&P 500 due to its 2.2 beta. Competitively, Cellectis S.A. is 74.00% more volatile than S&P 500, because of the 1.74 beta.

Liquidity

Celsion Corporation’s Current Ratio is 3.8 while its Quick Ratio is 3.8. On the competitive side is, Cellectis S.A. which has a 11.2 Current Ratio and a 11.2 Quick Ratio. Cellectis S.A. is better positioned to pay off short and long-term obligations compared to Celsion Corporation.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Celsion Corporation and Cellectis S.A.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Celsion Corporation	0	0	0	0.00
Cellectis S.A.	0	2	1	2.33

Cellectis S.A. on the other hand boasts of a $35.25 consensus price target and a 94.32% potential upside.

Institutional and Insider Ownership

Roughly 10.4% of Celsion Corporation shares are held by institutional investors while 29.4% of Cellectis S.A. are owned by institutional investors. Insiders held 0.4% of Celsion Corporation shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Celsion Corporation	-0.46%	1.41%	10.77%	-22.58%	-0.92%	53.19%
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%

For the past year Celsion Corporation was more bullish than Cellectis S.A.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.